Skip to content


Orladeyo (berotralstat) is a small molecule pharmaceutical. Berotralstat was first approved as Orladeyo on 2020-12-03. It has been approved in Europe to treat hereditary angioedemas. It is known to target plasma kallikrein. Orladeyo's patents are valid until 2039-11-01 (FDA).
Trade Name Orladeyo
Common Name Berotralstat
Indication hereditary angioedemas
Drug Class Enzyme inhibitors
Get full access now